Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Julia Close

General Oncology · UF

View

Dr. Allison Fitzgerald

General Oncology · Dana-Farber Cancer Institute

View

Dr. Lee Scheinbart

General Oncology · Burrell College of Osteopathic Medicine

View

Dr. Kathleen Cooney

GU Oncology · Duke

View

Dr. Rebecca Shatsky

Breast Oncology · UCSD

View

Dr. Robert Bast

Breast Oncology · MD Anderson Cancer Center

View

Dr. Sara Tolaney

Breast Oncology · Dana-Farber Cancer Institute

View

Dr. Jason Mouabbi

Breast Oncology · MD Anderson Cancer Center

View

Dr. Rebecca Miksad

GI Oncology · BMC

View

Dr. Matthew Kurian

Breast Oncology · St Elizabeth Healthcare

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    ECDr. Evan Chen

    Dr. Evan Chen

    Medical Oncology · General Oncology
    Dana-Farber Cancer Institute
    evanc

    Research

    Biology and Management of Acute Myeloid Leukemia With Mutated NPM1

    2025

    Via American Journal of Hematology

    Research

    Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy

    2025

    Via Blood Advances

    Research

    Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy

    2025

    Via Blood Advances

    Research

    The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia

    2025

    Via Bone Marrow Transplantation

    Research

    Response and outcomes of patients with mutated accelerated/blast-phase myeloproliferative neoplasms

    2025

    Via Blood Neoplasia

    Research

    Rapid epigenomic classification of acute leukemia

    2025

    Via Nature Genetics

    Research

    CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia

    2025

    Via Blood Advances

    Research

    No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse

    2025

    Via Blood Advances

    Research

    Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML

    2024

    Via Blood Advances

    Research

    Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL

    2024

    Via Blood Advances

    Research

    Incidence, duration, and severity of neutropenia in adults with B-cell acute lymphoblastic leukemia receiving blinatumomab consolidation

    2024

    Via Leukemia & Lymphoma

    Research

    Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL

    2024

    Via Journal of Clinical Oncology

    Research

    Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia

    2024

    Via Bone Marrow Transplantation

    Research

    Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia

    2024

    Via Bone Marrow Transplantation